The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Despite its well-publicised problems, the FDA is a happy place for ASX biotechs seeking drug or device approvals.

Q2 2025 Earnings Call Transcript August 7, 2025 Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.15, ...

The 20th anniversary of the 2005 Ashes series is a moment in time: a chance to capture the 12 England winners as they are now ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter ...

The emerging role of SETD2 in regulating immune cell function is shedding light on potential therapeutic strategies for a ...

In the fourth quarter of 2025, Black Diamond expects to disclose objective response rate (ORR) and preliminary duration of response (DOR) data from all patients (n=43) in the Phase 2 trial of ...

A team of researchers in Japan has identified a protein that may play a key role in driving the progression of advanced lung ...